Sonia Gandhi has won a fourth term as Congress president. She is now its longest serving head. Let us try to understand her. She isn’t particularly educated, and never attended college. Her certificate in English, perhaps in a 10-week course, is from an institute that no longer exists. Her Lok Sabha resume reads: “(i) Three years course in foreign languages (English & French) completed in 1964 at Istituto Santa Teresa, Turin (Italy). (ii) Certificate in English from Lennox Cook School, Cambridge (UK) completed in 1965.” Istituto Santa Teresa is a primary school and it isn’t clear why it’s mentioned. Lennox Cook School, now gone, was a tuition class unrelated to Cambridge University. Born in December 1946, Sonia got her certificate at 18. She’s had no education since. Her important qualification is for English, but those who watch her on television are struck by how poor her English is. She cannot express complex ideas in it. The Nehru-Gandhis were all dull students. Rajiv failed in Cambridge, Indira failed in Oxford, Sanjay failed in high school and Nehru didn’ t shine at Trinity. It’s unlikely Sonia knows much about world history. If she has read Seneca and Cicero she doesn’t show it. Those unburdened by education, like Sanjay Gandhi, find it easier to view things as either good or bad. How has this affected Sonia’s decisions? We shall see later. Sonia is slim and fit. At the dining table, she is probably disciplined. She looks younger than 64. Her aesthetic sense may be seen in her understated saris. She dresses in neat perfection, like an Italian woman. Her manner isn’t brusque. With the press she’s polite, and listens before responding. Her tone rarely changes. When attacking BJP leaders, she uses the oblique unko or unhonein. This distances her from them, while BJP is crude and direct with her. Her Hindi is broken, but she persists with it through a sentence, unlike urban Indians who mix Hindi with English. She retained her European passport a few years into marriage. This upsets us, but the initial reluctance to give it up actually reflects her lack of ambition. It also shows her middle-class values. How many of us cling on to our Indian passport when offered European citizenship? Her electoral record is strong: 114 seats in 1999, 145 seats in 2004 and 206 seats in 2009. She secured her position because of whom she married, but has held it through competence and achievement. She has revived Congress, and it is again the great political party of developing nations. Her husband would be proud of her, and she’s a better leader than he was. Rajiv allowed the murder of Delhi’s Sikhs. It took Sonia to do the right thing by them. She has run Congress efficiently. Sonia is tough; we see that from the lack of dissent in what was an anarchic party 15 years ago. That she and her son reject office helps her deny it to the undeserving. How difficult was it for her to understand our politics? Not very difficult. Understanding is easy if you can accept that Indians vote confessionally, like tribals. What’s difficult is to craft and apply policy that only a minority understands, but is good for India. Sonia declined to become prime minister in 2004, and has shown no inclination to the position since. The best thing she has done for India is to hand Manmohan charge of policy. An austere intellectual, he has taken the fun out of Sardarji jokes. The Indian does not see the appeal of the intellectual leader. He prefers charisma whether ascetic (Gandhi), heroic (Modi), or comic (Lalu). The thinking man, like Ambedkar, or Manmohan, must be smuggled into the cabinet. Two years after the Constitution he drafted took force, Bombay rejected Ambedkar in 1952. South Delhi rejected Manmohan, who saved our economy, in 1999. Neither man ever won a Lok Sabha seat. We wouldn’t have Manmohan without Sonia, and here’s where her view shows. She wants to do good, and she has. Sonia is accused of undermining Manmohan. But it isn’t easy to think of something he did because it was her whim.......contd ...

This stock can go upto 200 levels very soon. Operator want to sell the stock frm small investor.FII can shoot up anytime. Book value is around 200. dnt miss the opportunity....

Dear CaptAnil – It is not easy to give the estimates, we need to spend lot of time to study how many orders they are likely to execute in this quarters and how much revenue they are able cater. The worth of this estimates report can decided only when the deviation of the actual numbers are below + or – 5%. The real performance will come in the whole FY11. Hence, we need to wait for a while…. Advance cheers To download the earnings estimates of concurrent infra’s Q4FY10: //ww(w).ziddu(.)com/download/9049024/ConcurrentInfra_Q4FY10E_beandmake.pdf.html (Remove the two brackets) with thanks be and make //stockstowin.blogspot.c0m ...

AFTER a poor show in earnings for the fiscal year 2009, India’s leading biotech company Biocon has registered a good recovery in the current fiscal. With traction in its biopharma business and an improvement in the performance of its German subsidiary, Axicorp, the company holds attractive growth opportunities going forward. It is a good bet for investors interested in the mid-cap space. BUSINESS: The Bangalorebased company develops and manufacturers bio-pharmaceutical products for various medical ailments including cancer, diabetes and inflammatory diseases. The company’s biopharma business model straddles both products and services. The company’s statins business, which contributes nearly 30% to its revenues, has witnessed a strong growth in revenues. Further, the biopharma business has also gained from growth in domestic formulations business, insulins and immunosuppressants. Axicorp, the company’s low-margin trading business, has showed improvement and the subsidiary is gaining from supplying to the tender floated by the German insurer AOK. Through its two subsidiaries, Syngene and Clinigene, the company provides end-to-end services from pre-clinical discovery research to human clinical trials. It contributes nearly 15% to the company’s revenues. Biocon is also working on product development in view of the opportunity of launching biosimilars in the US and other regulated markets. The company has been steadily increasing spend on R&D . It now spends 7.5% of its revenues on R&D . FINANCIALS: The company’s net sales have grown at a compound annual growth rate (CAGR) of 24.4% over the past five fiscal years to reach around Rs 1,608.7 crore in FY09. The net profits have rather grown in an erratic manner during the same period. Heavy MTM losses, high depreciation due to large capex and rise in interest costs put pressure on net profit in the recent past. Despite this, the company has been consistently paying dividend for the past six years. It has incurred high capex over the past three years. As the company’s big-ticket capex are over, it is expected to generate more free cash flows going forward. However, the fact that the company earns majority of its revenues from lowmargin business segments of statins and Axicorp remains a concern. GROWTH OPPORTUNITIES: The patent for Atorvastatin is expiring in the UK in 2010 and in Germany in 2011 offering opportunity for the company to tap the -billion market . Given the increasing trend of R&D outsourcing, the company’s contract research service business is likely to see strong earnings inflow in the coming years. Strong ramp up in the scale and number of projects under Syngene are likely to augur near-term growth. Launch of biosimilars in regulated markets and commercialisation of its oral insulin programme IN-105 are long-term growth drivers for the company. A possible listing of its subsidiary, Syngene , could lead to value unlocking for the company and its shareholders. VALUATIONS: The company’s stock has been outperforming the Sensex since the middle of 2009. It is currently trading at a consolidated price-to-earnings value of 23. It is valued at two-and-a-half times its net sales. These valuations come on the back of promising growth prospects of the company across its various business segments. Investors with a long-term horizon are likely to benefit from the company’s promising growth story. ...

Dear - Have you gone through the Q4FY10E numbers of mine? How much deviation you are expecting for these numbers? Please share your views! with thanks be and make...

A report in BS dt March 20, 2010 (given below) has given details of the changes in indices to be effected shortly : Cipla will replace Sun Pharmaceuticals in Sensex from May 3, 2010. The sole pharmaceutical company featuring in the benchmark index will see the weightage of the sector decline marginally to 0.66% from 1% earlier in the Sensex. The index committee of the BSE in its meeting held on March 19 has decided to revise the composition of its indices. Sun Pharmaceuticals with Rs 35,131 crore market capitalisation is on top of the market cap ranking in pharmaceutical companies ahead of Cipla, which current market cap stands at Rs 26,781 crore. Sun Pharmaceutical was entered in the Sensex in place of Mahindra Satyam (formerly Satyam Computer Services) on January 12, 2010. The committee has also revised the composites of three broader indices – BSE-100, BSE-200 and BSE-500 index w.e.f March 29. Lupin, NHPC, Shriram Transport Finance Company and UltraTech Cement included in BSE-100 index in place of Asian Paints, Glaxosmithkline Pharmaceuticals, Bajaj Finserv and Mahanagar Telephone Nigam. The BSE-200 index replaces 16 companies and BSE-500 index has reshuffled 32 companies, the BSE said in its statement." MY COMMENTS : We also need to see what changes, if any,will come in NIFTY. We have to see how the trading pattern on BSE will undergo any change consequent on the above changes. Valuations also may undergo some changes consequently....

Chief, i am not much worried about rate hike.It seems that more than the markets,the analysts in cnbc is more worried about rate hikes.Don`t blame them , they have to run their shop.,IN 2008 when the market was at 21000 ,the repo rate was at 7.75%.Now even after the increase it is 5% only.A lot of room still left for upmove.I am not worried about inflation also.We can not keep the rate of of rice and onion at rs.5 forever.Let it increase and let the farmers also make some money.Think about inclusive growth.,In 80`s a cup of tea was sold at 10 paise per cup.Now it is 5 rs.per cup.How many of us stopped drinking tea because of this.,In US the same cup of tea is sold for 50 rs(converted to INR).When we start selling tea at rs.50 we will be called a `SUPER POWER`...

Market is expecting an FDI Policy decision in Tobacco

Market is expecting an FDI Policy decision in Tobacco Industry today. As Per Information, FDI in tobacco may be banned.


Swastika PMS

Market is expecting an FDI Policy decision in Tobacco Industry today. As Per Information, FDI in tobacco may be banned.


Swastika PMS...

EdServ Softsystems ltd has launched an Educational Service Portal

EdServ Softsystems ltd has launched an Educational Service Portal called "Lampsglow"

Swastika PMS...

SE Investments Board is considering Sub Division of Shares

Swastika PMS...

L&T bags project worth Rs 1400 Crore

L&T Signs Agreement for Six Laning of Road -NH-8A on DBFOT basis. The project is costing Rs 1400 crore and to be completed within 30 months.

Swastika PMS...

Wintac Ltd has approved rights issue

Wintac Ltd has approved rights issue in ratio of 1:2 at price of Rs 30/- Per share

Swastika PMS...

Apollo To invest Rs 360 Crore

Apollo To invest Rs 360 Crore across various cities in India and the proposals are at preliminary stage

Swastika PMS...

Subex Ltd has approved issue of 40 lacs share

Subex Ltd has approved issue of 40 lacs share on preferential basis to promoters at Rs 80 per share.

Swastika PMS...

TATA COMM Q3 Numbers Out:
Standalone Net Profit at Rs. 281.80 Cr Vs Rs. 82.19 Cr (+242.86%) (YoY)
standalone Net Sales at Rs. 769.75 Cr Vs Rs. 999.48 Cr (-22.98%) (YoY)

Swastika PMS...

Income tax officials visit Omaxe offices

Income tax officials visit Omaxe offices, IT officials verifying tax related documents of Omaxe.

Regards
Swastika PMS ...